Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Medicine and Dentistry

• Multiple Sclerosis 100%
• Placebo 100%
• Amaurosis 100%
• Patient 57%
• Therapeutic Procedure 28%
• Recurrence Risk 14%
• Diseases 7%
• Complication 7%
• Monoclonal Antibody 7%
• Follow up 7%
• Interleukin 2 7%
• Adverse Event 7%
• Intention-to-Treat Analysis 7%
• Disease Activity 7%
• Monotherapy 7%
• Chemotherapeutic Agent 7%
• Exanthem 7%
• Subcutaneous Injection 7%
• Drug 7%
• Interleukin 2 Receptor 7%
• Injection 7%
• Pharmacist 7%
• Analysis 7%
• Inpatient 7%
• Relapse 7%
• Voice 7%
• Personnel 7%
• Psoas Abscess 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Sclerosis 100%
• Blindness 100%
• Daclizumab 100%
• Recurrence Risk 14%
• Diseases 7%
• Adverse Event 7%
• Monotherapy 7%
• Monoclonal Antibody 7%
• Complication 7%
• Subcutaneous Injection 7%
• Rash 7%
• Drug 7%
• Disease Activity 7%
• Relapse 7%
• Turkey (Bird) 7%
• Interleukin 2 7%
• Interleukin 2 Receptor 7%
• Psoas Abscess 7%

Immunology and Microbiology

• Relapsing Remitting Multiple Sclerosis 100%
• Daclizumab 100%
• Multiple Sclerosis 14%
• Reduction (Chemistry) 14%
• Monoclonal Antibodies 7%
• CD25 7%
• Interleukin 2 Receptor 7%
• Interleukin 2 7%
• Electric Potential 7%
• Turkey (Bird) 7%
• Abscess 7%
• Interactive Voice Response System 7%